Effects of inflammatory and anti-inflammatory cytokines on the bone

European Journal of Clinical Investigation

Volumn 41, Issue 12, 2011, Pages 1361-1366

  Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bone; Cytokine; Immunology; Inflammation

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; BETA INTERFERON; CERTOLIZUMAB PEGOL; COLONY STIMULATING FACTOR; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA;

BONE; CYTOKINE PRODUCTION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE; OSSIFICATION; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS;

BONE AND BONES; BONE RESORPTION; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, IMMUNOLOGICAL;

EID: 81355161590     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02545.x     Document Type: Review

References (55)

1. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304.
2. Anderson DM, Maraskovsky E, Billingsley WL, Sauter B, Steinman RM, Choi Y et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
3. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-80.
4. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
5. Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
7. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Theum 2000;43:2143-51.
8. Schett G, Teitelbaum SL. Osteoclasts and arthritis. J Bone Miner Res 2009;24:1142-6.
9. Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-7.
10. Schett G, Kiechl S, Weger S et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006;166:2495-501.
11. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;5484:1504-8.
12. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
13. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
14. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
15. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
16. Takayanagi H, Iizuka H, Juji T et al. Involvement of receptor activator of nuclear factor kappa-B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
17. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
18. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
19. Redlich K, Hayer S, Maier A et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-92.
20. Romas E, Sims NA, Hards DK et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161:1419-27.
21. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
22. Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309.
23. Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000;275:27307-10.
24. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997;100:1557-65.
25. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
26. Li P, Schwarz EM, O'Keefe MaL, Boyce BF, Xing L. RANK signaling is not required for TNF-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Min Res 2004;19:207-13.
27. Herman S, Muller RB, Kronke G et al. Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 2008;58:3041-50.
28. Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995;182:1461-8.
29. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990;145:3297-303.
30. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 2008;283:11535-40.
31. Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009;60:2747-56.
32. Ohsugi Y, Kumaki K, Taga T et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8.
33. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004;113:379-89.
34. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002;169:3353-62.
35. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7.
36. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-90.
37. Zwerina J et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007;104:11742-7.
38. Horwood NJ et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 1998;101:595-603.
39. Udagawa N et al. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 1997;185:1005-12.
40. Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011;26:704-17.
41. Zaiss MM, Kurowska-Stolarska M, Böhm C, Gary R, Scholtysek C, Stolarski B et al. Interleukin (IL)-33 shifts the balance from osteoclast to alternatively-activated macrophage differentiation and protects from TNFa-mediated bone loss. J Immunol. 2011; in press.
42. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
43. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010;184:3336-40.
44. Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82.
45. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A. et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-659.
46. Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, Bouralexis S et al. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 2008;181:5720-9.
47. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001;166:4915-21.
48. Ju JH, Cho ML, Moon YM, Oh HJ, Park JS, Jhun JY et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008;181:1507-18.
49. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005;115:3418-27.
50. Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009;114:4517-26.
51. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416:744-9.
52. Takayanagi H, Ogasawara K, Hida S et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-5.
53. Djaafar S, Pierroz DD, Chicheportiche R, Zheng XX, Ferrari SL, Ferrari-Lacraz S. Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis Rheum 2010;62:3300-10.
54. Xu LX, Kukita T, Kukita A, Otsuka T, Niho Y, Iijima T. Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J Cell Physiol 1995;165:624-9.
55. Shioi A, Teitelbaum SL, Ross FP, Welgus HG, Suzuki H, Ohara J et al. Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem 1991;47:272-7.